Abstract
Purpose
Despite continued development of targeted therapies for children with cancer, patients continue to experience an array of unwanted side effects. Children with solid tumors may experience constipation as a result many treatment variables. Our objective was to investigate the prevalence and treatment of constipation in hospitalized children with solid tumors treated with chemotherapy.
Methods
We retrospectively analyzed data from 48 children’s hospitals in the Pediatric Health Information System, extracting patients 0–21 years of age with a solid tumor diagnosis hospitalized from October 2015-December 2019. Primary study outcome investigated which solid tumor subgroups received the diagnosis of constipation or received the most constipation medications while receiving chemotherapy for a cancer diagnosis.
Results
We identified 13,375 unique patients with a solid tumor diagnosis receiving chemotherapy. Constipation was the most common gastrointestinal complaint with 8,658 (64.7%; 95% Cl: 63.9–65.5%) meeting our defined constipation diagnosis. Bone cancers had the highest percentage (69.9%) of patients with constipation, while Hodgkin’s lymphoma had the lowest, though 52.1% of patients were affected. A total of 44% (n = 35,301) of encounters received an opioid at some point during admission. Of patients receiving constipation medications, the most commonly prescribed was poly-ethyl glycol (n = 25,175, 31.7%), followed by docusate (n = 11,297, 14.2%), senna (n = 10,325, 13.0%), and lactulose (n = 5,501, 6.9%).
Conclusions
Constipation is the most common gastrointestinal issue that children with solid tumors experience while receiving chemotherapy. Increased attention should be given to constipation prophylaxis and treatment in children with solid tumors undergoing chemotherapy.